FDA Issues CBD Report to Congress

FDA

In an important step on the path toward a better public understanding of cannabidiol products, benefits, and risks, this month the FDA issues CBD report to Congress

While the U.S. Food and Drug Administration (FDA) was more than a week behind the deadline set by the Further Consolidated Appropriations Act of 2020, the document issued extensive outlines the work done so far to regulate the legality and sale of CBD.

CBD as a Dietary Supplement

While hemp was confirmed legal under the 2018 Farm Bill, the FDA, CBD hemp farmers, and product manufacturers are not on the same page. Despite the strong anecdotal and independent scientific evidence regarding the benefits of cannabinoids for a wide variety of symptoms, federal regulations have lagged behind.

For example, companies are unable to advertise the impacts CBD has on the body’s endocannabinoid system, despite the numerous studies showing its results. These unclear regulations have led to confusion among the public seeking relief from everything from chronic pain to insomnia.

The new CBD report issued to Congress states that the FDA is now looking at new rules that would classify CBD as a dietary supplement. This would allow for official dosage and usage recommendations, which increases consumer confidence.

Until the rules and guidelines are in place, the FDA will also look at the creation of a risk-based enforcement discretion policy. This will make enforcement more transparent and uniform for the entire nation.

CBD in Food, Beverages, and Cosmetics

Because hemp-based products have always been legal, many enterprising companies have produced candies, snacks, and drinks, along with topical, cosmetic products infused with the benefits of cannabis. With the new CBD FDA reporting process, there is little change in the official understanding of these products.

The report states that FDA officials need more data to show not only effectiveness, but safety. They encourage stakeholders to share more information about their edible products to address their safety concerns.

They also continue to underscore the limited data available on topical use of CBD. Since officials believe there is not enough known about CBD, the news from the report is that there should continue to be no claims in marketing topical products. This includes highlighting the function or therapeutic benefits of the product.

FDA to Learn About Different Hemp Extracts

Furthermore, the FDA announced that it is planning to readdress their study of different hemp extracts. For example, CBD companies may fully comprehend the differences between “full spectrum,” “broad spectrum,” and CBD isolates. But the terms can be confusing to consumers u, and specific definitions from the FDA will provide clarifications.

Another takeaway from the report is that the agency will begin to focus on products currently on the market to see if any have been mislabeled or changed in a way that causes safety concerns to users. This should work to provide a deeper understanding for customers and federal officials alike.

Questions about this CBD News?

To learn more about cannabis-derived CBD oil, capsules, and topicals, visit Vimtality.com for a glossary of terms and other CBD news.